is often recommended. Such treatment augmentations can include lithium pharmacology, thyroid hormone augmentation, amisulpride, buspirone, bupropion, Guanfacine, stimulants, and mirtazapine. Additionally, if the person also has seasonal affective disorder, light therapy can be useful in helping augment therapeutic effects. Epidemiology Globally dysthymia occurs in about 105 million people a year (1.5% of the population). It is 38% more common in women (1.8% of women) than in men (1.3% of men). The lifetime prevalence rate of dysthymia in community settings appears to range from 3 to 6% in the United States. However, in primary care settings the rate is higher ranging from 5 to 15 percent. United States prevalence rates tend to be somewhat higher than rates in other countries. See also Anhedonia, a symptom of dysthymia characterized by a decreased or absent ability to enjoy a sense of pleasure Atypical depression Blunted affect, a symptom of PTSD, schizophrenia, and ASPD involving decreased or absent emotional response Dysphoria, a state of feeling unwell or unhappy Epigenetics of depression List of medications used to treat major depressive disorder or dysthymia References External links NIMH Depression Page Bipolar spectrum Depression (mood) Mood disorders